Edesa Biotech | 8-K: FY2026 Q2 Revenue: USD 0

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.49, missing the estimate of USD -0.26.

EBIT: As of FY2026 Q2, the actual value is USD -4.297 M.

The provided Form 8-K for Edesa Biotech, Inc. announces the issuance of a press release on May 14, 2026, detailing financial results for the three and six months ended March 31, 2026 . However, the actual financial results, operational metrics, or any forward-looking guidance are not included within the text of this Form 8-K itself . Therefore, no specific financial or operational metrics can be extracted from the provided reference .

Source: Earnings Watch The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.